Feasibility of fluorescence imaging at microdosing using a hybrid PSMA tracer during robot-assisted radical prostatectomy in a large animal model
Tóm tắt
With the rise of prostate-specific membrane antigen (PSMA) radioguided surgery, which is performed using a microdosing regime, demand for visual target confirmation via fluorescence guidance is growing. While proven very effective for radiotracers, microdosing approaches the detection limit for fluorescence imaging. Thus, utility will be highly dependent on the tracer performance, the sensitivity of the fluorescence camera used, and the degree of background signal. Using a porcine model the ability to perform robot-assisted radical prostatectomy under fluorescence guidance using the bimodal or rather hybrid PSMA tracer (99mTc-EuK-(SO3)Cy5-mas3) was studied, while employing the tracer in a microdosing regime. This was followed by ex vivo evaluation in surgical specimens obtained from prostate cancer patients. T50% blood and T50% urine were reached at 85 min and 390 min, in, respectively, blood and urine. Surgical fluorescence imaging allowed visualization of the prostate gland based on the basal PSMA-expression in porcine prostate. Together, in vivo visualization of the prostate and urinary excretion suggests at least an interval of > 7 h between tracer administration and surgery. Confocal microscopy of excised tissues confirmed tracer uptake in kidney and prostate, which was confirmed with PSMA IHC. No fluorescence was detected in other excised tissues. Tumor identification based on ex vivo fluorescence imaging of human prostate cancer specimens correlated with PSMA IHC. Intraoperative PSMA-mediated fluorescence imaging with a microdosing approach was shown to be feasible. Furthermore, EuK‐(SO3)Cy5‐mas3 allowed tumor identification in human prostate samples, underlining the translational potential of this novel tracer. Trial registration Approval for use of biological material for research purposes was provided by the Translational Research Board of the Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital (NKI-AvL) under reference IRBm19-273 (22/10/2019).
Tài liệu tham khảo
Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68:530–4.
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62.
Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58:67s–76s.
Schottelius M, Wirtz M, Eiber M, Maurer T, Wester HJ. [(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res. 2015;5:68.
Mix M, Reichel K, Stoykow C, Bartholomä M, Drendel V, Gourni E, et al. Performance of (111)In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy. Eur J Nucl Med Mol Imaging. 2018;45:2062–70.
Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, et al. Preclinical evaluation and first patient application of Tc-99m-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017;58:235–42.
Bois F, Noirot C, Dietemann S, Mainta IC, Zilli T, Garibotto V, et al. [(68)Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review. Am J Nucl Med Mol Imaging. 2020;10:349–74.
Fleming GA. 12 Regulatory considerations for early clinical development of drugs for diabetes, obesity, and cardiometabolic disorders. In: Krentz AJ, Heinemann L, Hompesch M, editors. Translational research methods for diabetes, obesity and cardiometabolic drug development: a focus on early phase clinical studies. London: Springer; 2015. p. 283.
Kummar S, Doroshow JH, Tomaszewski JE, Calvert AH, Lobbezoo M, Giaccone G, et al. Phase 0 clinical trials: recommendations from the task force on methodology for the development of innovative cancer therapies. Eur J Cancer. 2009;45:741–6.
Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, et al. (99m)Technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol. 2019;75:659–66.
Horn T, Krönke M, Rauscher I, Haller B, Robu S, Wester HJ, et al. Single lesion on prostate-specific membrane antigen-ligand positron emission tomography and low prostate-specific antigen are prognostic factors for a favorable biochemical response to prostate-specific membrane antigen-targeted radioguided surgery in recurrent prostate cancer. Eur Urol. 2019;76:517–23.
Knipper S, Ascalone L, Ziegler B, Hohenhorst JL, Simon R, Berliner C, et al. Salvage surgery in patients with local recurrence after radical prostatectomy. Eur Urol. 2021;79:537–44.
Dell’Oglio P, Meershoek P, Maurer T, Wit EMK, van Leeuwen PJ, van der Poel HG, et al. A DROP-IN gamma probe for robot-assisted radioguided surgery of lymph nodes during radical prostatectomy. Eur Urol. 2021;79:124–32.
van Leeuwen FWB, van Oosterom MN, Meershoek P, van Leeuwen PJ, Berliner C, van der Poel HG, et al. Minimal-invasive robot-assisted image-guided resection of prostate-specific membrane antigen-positive lymph nodes in recurrent prostate cancer. Clin Nucl Med. 2019;44:580–1.
Hensbergen AW, van Willigen DM, van Beurden F, van Leeuwen PJ, Buckle T, Schottelius M, et al. Image-guided surgery: Are we getting the most out of small-molecule prostate-specific-membrane-antigen-targeted tracers? Bioconjug Chem. 2020;31:375–95.
Niaz MO, Sun M, Ramirez-Fort MK, Niaz MJ. Prostate-specific membrane antigen based antibody-drug conjugates for metastatic castration-resistance prostate cancer. Cureus. 2020;12:e7147.
Urbán S, Meyer C, Dahlbom M, Farkas I, Sipka G, Besenyi Z, et al. Radiation dosimetry of (99m)Tc-PSMA I&S: a single-center prospective study. J Nucl Med. 2021;62:1075–81.
van Leeuwen FW, van der Poel HG. Surgical guidance in prostate cancer: “from molecule to man” translations. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22:1304–6.
Piron S, Verhoeven J, De Coster E, Descamps B, Kersemans K, Pieters L, et al. Impact of the molar activity and PSMA expression level on [18F]AlF-PSMA-11 uptake in prostate cancer. Sci Rep. 2021;11:22623.
KleinJan GH, Bunschoten A, van den Berg NS, Olmos RA, Klop WM, Horenblas S, et al. Fluorescence guided surgery and tracer-dose, fact or fiction? Eur J Nucl Med Mol Imaging. 2016;43:1857–67.
Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, et al. Tumor-specific uptake of fluorescent bevacizumab-IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:2730–41.
van Leeuwen FWB, Schottelius M, Brouwer OR, Vidal-Sicart S, Achilefu S, Klode J, et al. Trending: radioactive and fluorescent bimodal/hybrid tracers as multiplexing solutions for surgical guidance. J Nucl Med. 2020;61:13–9.
Eder AC, Omrane MA, Stadlbauer S, Roscher M, Khoder WY, Gratzke C, et al. The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging. Eur J Nucl Med Mol Imaging. 2021;48:2057–8.
Aras O, Demirdag C, Kommidi H, Guo H, Pavlova I, Aygun A, et al. Small molecule, multimodal, [(18)F]-PET and fluorescence imaging agent targeting prostate-specific membrane antigen: first-in-human study. Clin Genitourin Cancer. 2021;19:405–16.
Hensbergen AW, Buckle T, van Willigen DM, Schottelius M, Welling MM, van der Wijk FA, et al. Hybrid tracers based on cyanine backbones targeting prostate-specific membrane antigen: tuning pharmacokinetic properties and exploring dye-protein interaction. J Nucl Med. 2020;61:234–41.
de Vries HM, Bekers E, van Oosterom MN, Krakullukcu MB, van der Poel HG, van Leeuwen FWB, et al. c-MET receptor-targeted fluorescence on the road to image-guided surgery in penile squamous cell carcinoma patients. J Nucl Med. 2021;63:51–6.
Buckle T, van Alphen M, van Oosterom MN, van Beurden F, Heimburger N, van der Wal JE, et al. Translation of c-met targeted image-guided surgery solutions in oral cavity cancer-initial proof of concept data. Cancers (Basel). 2021;13:2674.
Nováková Z, Foss CA, Copeland BT, Morath V, Baranová P, Havlínová B, et al. Novel monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA) as research and theranostic tools. Prostate. 2017;77:749–64.
Rovenská M, Hlouchová K, Šácha P, Mlčochová P, Horák V, Zámečník J, et al. Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate. 2008;68:171–82.
Baranski A-C, Schäfer M, Bauder-Wüst U, Roscher M, Schmidt J, Stenau E, et al. PSMA-11 derived dual-labeled PSMA-inhibitors for preoperative PET imaging and precise fluorescence-guided surgery of prostate cancer. J Nucl Med. 2018;59:639–45.
van der Poel HG, Buckle T, Brouwer OR, Valdes Olmos RA, van Leeuwen FW. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur Urol. 2011;60:826–33.
Schottelius M, Wurzer A, Wissmiller K, Beck R, Koch M, Gorpas D, et al. Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer. J Nucl Med. 2019;60:71–8.
Nishio N, van den Berg NS, van Keulen S, Martin BA, Fakurnejad S, Zhou Q, et al. Optimal dosing strategy for fluorescence-guided surgery with panitumumab-IRDye800CW in head and neck cancer. Mol Imaging Biol. 2020;22:156–64.
Thompson C. Prostate molecular targeting to enhance surgery using IR800 IAB2M. ISRCTN registry; 2018.
van Leeuwen FWB, Cornelissen B, Caobelli F, Evangelista L, Rbah-Vidal L, Del Vecchio S, et al. Generation of fluorescently labeled tracers—Which features influence the translational potential? EJNMMI Radiopharm Chem. 2017;2:15.
Lim E. Prostate-specific membrane antigen in prostate cancer imaging and treatment. Transl Cancer Res. 2018;7:S676–89.
Schlake A, Dell’Oglio P, Devriendt N, Stammeleer L, Binetti A, Bauwens K, et al. First robot-assisted radical prostatectomy in a client-owned Bernese mountain dog with prostatic adenocarcinoma. Vet Surg. 2020;49:1458–66.
Buckle T, van Willigen DM, Spa SJ, Hensbergen AW, van der Wal S, de Korne CM, et al. Tracers for fluorescence-guided surgery: how elongation of the polymethine chain in cyanine dyes alters the pharmacokinetics of a dual-modality c[RGDyK] tracer. J Nucl Med. 2018;59:986–92.
Burggraaf J, Kamerling IM, Gordon PB, Schrier L, de Kam ML, Kales AJ, et al. Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. Nat Med. 2015;21:955–61.
de Jongh SJ, Voskuil FJ, Schmidt I, Karrenbeld A, Kats-Ugurlu G, Meersma GJ, et al. C-Met targeted fluorescence molecular endoscopy in Barrett’s esophagus patients and identification of outcome parameters for phase-I studies. Theranostics. 2020;10:5357–67.
Zanoni DK, Stambuk HE, Madajewski B, Montero PH, Matsuura D, Busam KJ, et al. Use of ultrasmall core-shell fluorescent silica nanoparticles for image-guided sentinel lymph node biopsy in head and neck melanoma: a nonrandomized clinical trial. JAMA Netw Open. 2021;4:e211936.
Laios A, Volpi D, Tullis ID, Woodward M, Kennedy S, Pathiraja PN, et al. A prospective pilot study of detection of sentinel lymph nodes in gynaecological cancers using a novel near infrared fluorescence imaging system. BMC Res Notes. 2015;8:608.
van Leeuwen FW, Hardwick JC, van Erkel AR. Luminescence-based imaging approaches in the field of interventional molecular imaging. Radiology. 2015;276:12–29.
de Jongh SJ, Tjalma JJJ, Koller M, Linssen MD, Vonk J, Dobosz M, et al. Back-table fluorescence-guided imaging for circumferential resection margin evaluation using bevacizumab-800CW in patients with locally advanced rectal cancer. J Nucl Med. 2020;61:655–61.
Hekman MC, Rijpkema M, Muselaers CH, Oosterwijk E, Hulsbergen-Van de Kaa CA, Boerman OC, et al. Tumor-targeted dual-modality imaging to improve intraoperative visualization of clear cell renal cell carcinoma: a first in man study. Theranostics. 2018;8:2161–70.
Mazzone E, Dell’Oglio P, Grivas N, Wit E, Donswijk M, Briganti A, et al. Diagnostic value, oncological outcomes and safety profile of image-guided surgery technologies during robot-assisted lymph node dissection with sentinel node biopsy for prostate cancer. J Nucl Med. 2021;62:1363–71.